Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

July 23, 2026 7:09 AM

Canaccord analyst Gary Nachman reiterated a Buy rating and $95.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "IONS’ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found